Skip to main content
Clinical Trials/NCT02964676
NCT02964676UnknownNot Applicable

Clinical Efficacy and Safety of Minimally Invasive Glaucoma Surgery on Chinese Primary Angle Closure Glaucoma

Shanghai Eye Disease Prevention and Treatment Center0 sites246 target enrollmentStarted: January 1, 2017Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Enrollment
246
Primary Endpoint
success rate of IOP reduction

Study Overview

Brief Summary

To evaluate the clinical efficacy (intraocular pressure reduction , success rate, the number of antiglaucoma medication) and safety of ab interno trabeculectomy (AIT) with Trabectome in Chinese PACG .

Detailed Description

A randomized, single blind, positive parallel control study method was used.This prospective case series will recruit 246 Chinese POAG, 123 cases in the experimental group will receive AIT treatment and 123 cases in the control group will receive trabeculectomy(Trab) surgery.Measurements of intraocular pressure(IOP) , visual acuity, refraction, slit lamp examination of the anterior segment and fundus, optical coherence tomography(OCT) to detect retinal nerve fiber layer thickness, macular thickness, visual field, gonioscopy and ultrasonic biological microscopy (UBM) will be recorded.They will be followed up for 12 months. The main outcome is success rate of IOP reduction and the other outcome are the number of antiglaucoma medication and complications .

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Investigator)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Primary Angle Closure Glaucoma (PACG) with visible trabecular meshwork from 90︒ to 180︒ on gonioscopy and IOP couldn't be controlled ≤21mmHg with pilocarpine eye drop only.
  • •willing to accept the antiglaucoma surgery
  • •volunteer to participate in this study and be able to follow up on time
  • •previous antiglaucoma filtering surgery or laser surgery(LPI, SLT) and previous cataract surgery were not ruled out

Exclusion Criteria

  • •visual acuity lower than HM or central tubular visual field
  • •corneal edema or large pterygium affecting the observation of anterior angle
  • •the demarcation of the scleral process and trabecular meshwork is not clear on gonioscopy
  • •new vessels on the iris surface or in the anterior angle chamber
  • •the eye received surgery is the only eye with visual function, that is the contralateral eye is blind
  • •requiring long-term use of anticoagulant drugs for systemic reasons
  • •abnormal coagulation function
  • •with specific clear scar physique
  • •cannot participate in follow-up

Arms & Interventions

AIT group

Experimental

PACG in AIT group will receive ab interno trabeculectomy with Trabectome and before AIT, Laser Peripheral Iridectomy (LPI) will be performed first.

Intervention: ab interno trabeculectomy with Trabectome (Procedure)

Trab group

Active Comparator

PACG in AIT group will receive trabeculectomy.

Intervention: trabeculectomy (Procedure)

Outcomes

Primary Outcomes

success rate of IOP reduction

Time Frame: 12 months

IOP ≤21mmHg and IOP reduction rate ≥20% with or without antiglaucoma medications and without additional glaucoma surgery

Secondary Outcomes

  • 24-hour IOP fluctuations(12 months)
  • number of antiglaucoma medication(12 months)
  • complication rate(12 months)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials

Clinical Efficacy and Safety of Minimally... | Clinical Trial